Superiority of interferon-free regimens for chronic hepatitis C: The effect on health-related quality of life and work productivity

Medicine (United States)

Volumn 96, Issue 7, 2017, Pages

  Younossi, Zobair M ^a,b   Stepanova, Maria ^b,c   Esteban, Rafael ^d   Jacobson, Ira ^e   Zeuzem, Stefan ^f   Sulkowski, Mark ^g   Henry, Linda ^b,c   Nader, Fatema ^b,c   Cable, Rebecca ^a,b   Afendy, Mariam ^a,b   Hunt, Sharon ^b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Direct acting antivirals; Fatigue; Work productivity

Indexed keywords

ALANINE AMINOTRANSFERASE; HEMOGLOBIN; INTERFERON; RIBAVIRIN; SOFOSBUVIR; VIRUS RNA; ANTIVIRUS AGENT;

ABSENTEEISM; ADULT; ARTHRALGIA; ARTICLE; ASTHENIA; CHRONIC HEPATITIS C; CHRONIC LIVER DISEASE QUESTIONNAIRE; DEPRESSION; FATIGUE; FEMALE; FLU LIKE SYNDROME; FUNCTIONAL ASSESSMENT OF CHRONIC ILLNESS THERAPY FATIGUE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MIDDLE AGED; MUSCULOSKELETAL DISEASE; MYALGIA; NEUROLOGIC DISEASE; OPEN STUDY; PATIENT-REPORTED OUTCOME; PHASE 3 CLINICAL TRIAL; PHYSICAL WELL-BEING; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY OF LIFE; RESPIRATORY TRACT DISEASE ASSESSMENT; SHORT FORM 36; SKIN DISEASE; SOCIAL INTERACTION; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; WORK PRODUCTIVITY AND ACTIVITY SPECIFIC HEALTH PROBLEM; CLINICAL TRIAL; HEPATITIS C, CHRONIC; JOB PERFORMANCE; MULTICENTER STUDY; PSYCHOLOGY; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; QUALITY OF LIFE; RIBAVIRIN; SOFOSBUVIR; TREATMENT OUTCOME; WORK PERFORMANCE;

EID: 85013650566     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000005914     Document Type: Article

References (23)

1. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013;368:1878-87.
2. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014;370:1993-2001.
3. Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015;15:397-404.
4. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology 2015;149:1454-61.
5. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014;370:1889-98.
6. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014;370: 1483-93.
7. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014;370:1879-88.
8. Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7.
9. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis 2014;46(suppl 5):S186-96.
10. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvir-based treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2014;12:1349-59.
11. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: the impact on patient-reported outcomes. J Infect Dis 2015;212:367-77.
12. Younossi ZM, Stepanova M, Marcellin P, et al. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: results from the ION-1,-2, and-3 clinical trials. Hepatology 2015;61: 1798-808.
13. Mchutchison JG, Ware JE, Bayliss MS, et al. The effects of interferon alpha-2b in combination with ribavirin on health related quality of life and work productivity. J Hepatol 2001;34:140-7.
14. Hassanein T, Cooksley G, Sulkowski M, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on healthrelated quality of life in chronic hepatitis C. J Hepatol 2004;40:675-81.
15. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001;10:405-13.
16. Webster K, Odom L, Peterman A, et al. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system: validation of version 4 of the core questionnaire. Qual Life Res 1999;8:604.
17. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut 1999;45:295-300.
18. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993;4:353-65.
19. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92.
20. Younossi ZM, Stepanova M, Afdhal N, et al. Improvement of healthrelated quality of life and work productivity in chronic hepatitis C patients with early and advanced fibrosis treated with ledipasvir and sofosbuvir. J Hepatol 2015;63:337-45.
21. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus. J Viral Hepat 2016;23:857-65.
22. Younossi ZM, Stepanova M, Sulkowski M, et al. Ribavirin-free regimen with sofosbuvir and velpatasvir is associated with high efficacy and improvement of patient-reported outcomes in patients with genotypes 2 and 3 chronic hepatitis C: results from astral-2 and-3 clinical trials. Clin Infect Dis 2016;63:1042-8.
23. Younossi ZM, Stepanova M, Henry L, et al. An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens.Am J Gastroenterol 2016;111:808-16.